| 2026 |
| 03/09 | 456 | 462 | 450 | 458 | -3.78% | 29,400 | 29億7109万 | -4.98% |
| 03/06 | 472 | 483 | 462 | 476 | +1.06% | 16,500 | 30億8786万 | -1.45% |
| 03/05 | 460 | 474 | 460 | 471 | +4.43% | 35,600 | 30億5543万 | -2.69% |
| 03/04 | 461 | 464 | 438 | 451 | -5.45% | 129,800 | 29億2568万 | -7.01% |
| 03/03 | 488 | 490 | 472 | 477 | -2.45% | 54,400 | 30億9435万 | -1.85% |
| 03/02 | 486 | 493 | 482 | 489 | -1.01% | 39,200 | 31億7219万 | +0.62% |
| 02/27 | 480 | 498 | 478 | 494 | +4.22% | 46,200 | 32億463万 | +1.65% |
| 02/26 | 484 | 486 | 472 | 474 | -0.63% | 43,000 | 30億7489万 | -2.47% |
| 02/25 | 477 | 486 | 477 | 477 | 0% | 40,900 | 30億9435万 | -2.25% |
| 02/24 | 479 | 480 | 463 | 477 | 0% | 102,900 | 30億9435万 | -2.85% |
| 02/20 | 486 | 494 | 476 | 477 | -1.85% | 38,000 | 30億9435万 | -2.85% |
| 02/19 | 17:00 取締役候補者、監査役候補者並びに補欠監査役候補者の選任に関するお知らせ |
| 02/19 | 502 | 506 | 486 | 486 | -3.76% | 38,900 | 31億5273万 | -1.02% |
| 02/18 | 481 | 505 | 481 | 505 | +4.99% | 62,500 | 32億7599万 | +3.06% |
| 02/17 | 493 | 493 | 478 | 481 | -1.23% | 40,800 | 31億2030万 | -1.43% |
| 02/16 | 476 | 492 | 476 | 487 | +2.53% | 36,900 | 31億5922万 | -0.2% |
| 02/13 | 480 | 489 | 472 | 475 | -1.04% | 47,300 | 30億8137万 | -2.46% |
| 02/12 | 12:00 2025年12月期決算説明資料 |
| 02/12 | 12:00 事業計画及び成長可能性に関する説明資料 |
| 02/12 | 12:00 2025年12月期決算短信〔日本基準〕(非連結) |
| 02/12 | 498 | 503 | 474 | 480 | -3.23% | 85,200 | 31億1381万 | -1.23% |
| 02/10 | 487 | 504 | 487 | 496 | +1.43% | 42,600 | 32億1760万 | +2.06% |
| 02/09 | 491 | 495 | 484 | 489 | +0.2% | 43,100 | 31億7219万 | +0.82% |
| 02/06 | 492 | 495 | 484 | 488 | -1.61% | 27,200 | 31億6571万 | +0.62% |
| 02/05 | 499 | 503 | 489 | 496 | -0.4% | 59,900 | 32億1760万 | +2.06% |
| 02/04 | 482 | 505 | 474 | 498 | +3.32% | 144,000 | 32億3058万 | +2.05% |
| 02/03 | 487 | 487 | 479 | 482 | -0.62% | 50,400 | 31億2678万 | -2.03% |
| 02/02 | 490 | 493 | 480 | 485 | -1.62% | 73,300 | 31億4625万 | -2.41% |
| 01/30 | 482 | 496 | 478 | 493 | +2.28% | 89,000 | 31億9814万 | -1% |
| 01/29 | 482 | 483 | 470 | 482 | +0.21% | 101,600 | 31億2678万 | -2.82% |
| 01/28 | 496 | 496 | 481 | 481 | -2.83% | 128,700 | 31億2030万 | -2.83% |
| 01/27 | 513 | 549 | 486 | 495 | +3.34% | 1,429,100 | 32億1112万 | +0.2% |
| 01/26 | 17:00 SpiroChemとVeritas In Silico、mRNA標的化合物の共同探索研究に関する覚書締結完了のお知らせ |
| 01/26 | 488 | 514 | 479 | 479 | +0.21% | 155,900 | 31億732万 | -2.64% |
| 01/23 | 481 | 487 | 475 | 478 | -1.04% | 91,400 | 31億84万 | -3.04% |
| 01/22 | 494 | 499 | 481 | 483 | -2.23% | 161,000 | 31億3327万 | -2.03% |
| 01/21 | 495 | 512 | 493 | 494 | -5.9% | 297,200 | 32億463万 | 0% |
| 01/20 | 578 | 586 | 512 | 525 | -5.91% | 1,196,300 | 34億573万 | +6.28% |
| 01/19 | 13:30 東京慈恵会医科大学とVeritas In Silico,筋萎縮性側索硬化症(ALS)の治療に向けた新たな核酸医薬品に関する特許公開のお知らせ |
| 01/19 | 472 | 558 | 463 | 558 | +16.74% | 3,128,300 | 36億1980万 | +13.18% |
| 01/16 | 487 | 487 | 469 | 478 | -0.21% | 62,900 | 31億84万 | -2.45% |
| 01/15 | 462 | 480 | 459 | 479 | +4.59% | 88,100 | 31億732万 | -2.44% |
| 01/14 | 463 | 467 | 458 | 458 | -0.87% | 36,800 | 29億7109万 | -6.91% |
| 01/13 | 473 | 477 | 460 | 462 | -1.49% | 52,300 | 29億9704万 | -6.67% |
| 01/09 | 465 | 476 | 461 | 469 | +1.3% | 43,000 | 30億4245万 | -5.44% |
| 01/08 | 467 | 473 | 461 | 463 | -0.86% | 75,700 | 30億353万 | -6.84% |
| 01/07 | 480 | 480 | 465 | 467 | -2.51% | 108,300 | 30億2948万 | -6.41% |
| 01/06 | 482 | 493 | 477 | 479 | +0.84% | 80,600 | 31億732万 | -4.39% |
| 01/05 | 488 | 488 | 471 | 475 | -1.04% | 90,000 | 30億8137万 | -5.38% |
| 01/05 | 8:00 創薬プラットフォーム ibVIS の aibVIS へのアップグレードについて |
| 2025 |
| 12/30 | 509 | 513 | 478 | 480 | -6.25% | 337,100 | 31億1381万 | -4.76% |
| 12/29 | 560 | 584 | 512 | 512 | -5.19% | 584,500 | 33億2140万 | +1.39% |
| 12/26 | 621 | 622 | 525 | 540 | -10.15% | 1,139,100 | 35億304万 | +6.93% |
| 12/25 | 730 | 793 | 601 | 601 | -1.48% | 2,425,700 | 38億9875万 | +19.48% |
| 12/24 | 610 | 610 | 610 | 610 | +19.61% | 12,700 | 39億5713万 | +22.24% |
| 12/23 | 510 | 510 | 510 | 510 | +18.6% | 15,500 | 33億842万 | +2.82% |
| 12/22 | 15:30 mRNA標的核酸医薬品自社パイプライン特許出願のお知らせ |
| 12/22 | 452 | 458 | 428 | 430 | -6.32% | 67,100 | 27億8945万 | -13.48% |
| 12/19 | 460 | 464 | 458 | 459 | +0.22% | 32,200 | 29億7758万 | -8.38% |
| 12/18 | 468 | 473 | 458 | 458 | -1.29% | 35,200 | 29億7109万 | -9.31% |
| 12/17 | 485 | 485 | 463 | 464 | -5.31% | 46,500 | 30億1002万 | -8.84% |
| 12/16 | 499 | 506 | 485 | 490 | -0.41% | 40,300 | 31億7868万 | -4.48% |
| 12/15 | 17:00 事業計画及び成長可能性に関する説明資料 |
| 12/15 | 17:00 当社独自のドラッグデリバリーシステム「Perfusio」特許査定及び権利化手続完了のお知らせ |
| 12/15 | 491 | 493 | 488 | 492 | +0.2% | 14,500 | 31億9166万 | -4.65% |
| 12/12 | 487 | 499 | 487 | 491 | -0.41% | 17,200 | 31億8517万 | -5.21% |
| 12/11 | 498 | 498 | 485 | 493 | -1.4% | 28,000 | 31億9814万 | -5.37% |
| 12/10 | 495 | 506 | 495 | 500 | +0.6% | 29,600 | 32億4355万 | -4.58% |
| 12/09 | 495 | 498 | 495 | 497 | +0.4% | 10,600 | 32億2409万 | -5.51% |
| 12/08 | 509 | 511 | 495 | 495 | -4.07% | 24,200 | 32億1112万 | -6.25% |
| 12/05 | 508 | 516 | 500 | 516 | +1.18% | 18,300 | 33億4735万 | -2.64% |
| 12/04 | 498 | 510 | 492 | 510 | +2.62% | 20,400 | 33億842万 | -3.95% |
| 12/03 | 503 | 503 | 490 | 497 | -1.19% | 23,500 | 32億2409万 | -6.75% |
| 12/02 | 512 | 512 | 499 | 503 | -2.14% | 31,100 | 32億6301万 | -6.16% |
| 12/01 | 521 | 521 | 513 | 514 | -0.19% | 23,600 | 33億3437万 | -4.64% |
| 11/28 | 507 | 515 | 506 | 515 | +1.58% | 21,500 | 33億4086万 | -4.81% |
| 11/27 | 507 | 515 | 506 | 507 | -0.39% | 17,300 | 32億8896万 | -6.97% |
| 11/26 | 507 | 512 | 503 | 509 | +0.39% | 28,300 | 33億194万 | -7.12% |
| 11/25 | 515 | 515 | 504 | 507 | -0.59% | 28,400 | 32億8896万 | -7.99% |
| 11/21 | 500 | 510 | 498 | 510 | +0.99% | 40,400 | 33億842万 | -7.78% |
| 11/20 | 513 | 522 | 500 | 505 | 0% | 39,100 | 32億7599万 | -9.34% |
| 11/19 | 521 | 524 | 504 | 505 | -4.17% | 37,900 | 32億7599万 | -9.82% |
| 11/18 | 522 | 540 | 522 | 527 | +1.15% | 51,200 | 34億1870万 | -6.89% |
| 11/17 | 15:30 島根大学との肺移植後の機能不全を抑制する新たな医薬品の研究開発を目的とした共同研究開始のお知らせ |
| 11/17 | 538 | 538 | 511 | 521 | -3.16% | 50,000 | 33億7978万 | -9.08% |
| 11/14 | 562 | 564 | 520 | 538 | -4.27% | 86,900 | 34億9006万 | -7.4% |
| 11/13 | 573 | 573 | 562 | 562 | -1.23% | 9,500 | 36億4575万 | -4.26% |
| 11/12 | 558 | 581 | 555 | 569 | +2.34% | 75,900 | 36億9116万 | -4.05% |
| 11/11 | 16:00 2025年12月期第3四半期決算説明資料 |
| 11/11 | 16:00 2025年12月期第3四半期決算短信〔日本基準〕(非連結) |
| 11/11 | 16:00 機構改革及び人事異動に関するお知らせ |
| 11/11 | 565 | 565 | 555 | 556 | -1.24% | 16,500 | 36億683万 | -7.18% |
| 11/10 | 550 | 568 | 550 | 563 | +2.36% | 22,200 | 36億5224万 | -6.94% |
| 11/07 | 555 | 562 | 544 | 550 | -1.96% | 15,300 | 35億6791万 | -9.84% |
| 11/06 | 558 | 563 | 550 | 561 | +1.81% | 21,100 | 36億3927万 | -8.93% |
| 11/05 | 557 | 557 | 540 | 551 | -0.36% | 34,100 | 35億7439万 | -11.41% |
| 11/04 | 15:30 デクセリアルズ株式会社との高速かつ正確性の高い分光学的RNA構造測定法の確立を目的とする共同技術開発実施のおしらせ |
| 11/04 | 560 | 560 | 547 | 553 | -0.18% | 29,300 | 35億8737万 | -12.22% |
| 10/31 | 545 | 558 | 545 | 554 | +0.73% | 13,900 | 35億9386万 | -12.89% |
| 10/30 | 545 | 553 | 543 | 550 | +1.1% | 18,100 | 35億6791万 | -14.46% |
| 10/29 | 557 | 558 | 544 | 544 | -2.33% | 55,700 | 35億2899万 | -16.18% |
| 10/28 | 568 | 568 | 553 | 557 | -2.79% | 56,400 | 36億1332万 | -15.09% |
| 10/27 | 571 | 583 | 570 | 573 | +0.53% | 37,000 | 37億1711万 | -13.44% |
| 10/24 | 580 | 582 | 570 | 570 | -1.72% | 33,500 | 36億9765万 | -14.67% |
| 10/23 | 587 | 587 | 575 | 580 | -2.03% | 33,600 | 37億6252万 | -13.82% |
| 10/22 | 584 | 592 | 581 | 592 | +1.02% | 33,300 | 38億4037万 | -12.56% |
| 10/21 | 592 | 600 | 582 | 586 | -0.17% | 23,600 | 38億144万 | -13.95% |
| 10/20 | 580 | 593 | 577 | 587 | +2.44% | 33,000 | 38億793万 | -14.31% |
| 10/17 | 599 | 599 | 573 | 573 | -3.37% | 46,300 | 37億1711万 | -16.96% |
| 10/16 | 581 | 598 | 572 | 593 | +2.77% | 79,300 | 38億4685万 | -14.68% |
| 10/15 | 567 | 585 | 567 | 577 | -13.49% | 175,300 | 37億4306万 | -17.69% |
| 10/14 | 17:00 2025年12月期通期業績予想の修正に関するお知らせ |
| 10/14 | 685 | 690 | 666 | 667 | -4.03% | 66,400 | 43億2690万 | -5.66% |
| 10/10 | 722 | 722 | 695 | 695 | -3.87% | 27,100 | 45億854万 | -1.84% |
| 10/09 | 700 | 723 | 692 | 723 | +3.73% | 63,800 | 46億9018万 | +1.97% |
| 10/08 | 696 | 705 | 690 | 697 | -1.69% | 30,600 | 45億2151万 | -1.69% |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
